We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.

ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.

Clinical Trials

The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.

Science

Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.

Month: October 2014

Applications for Neuroprotection: The Next Therapeutic Category in Retina Medicine

Applications for Neuroprotection: The Next Therapeutic Category in Retina Medicine Retina Today – October 2014By Pravin U. Dugel, M.D. Leading retinal specialist and industry opinion leader Pravin U. Dugel, MD, discusses ONL Therapeutics’ core technology and its significant potential to treat retinal disease. Read the Article

October 11, 2014
ONL Therapeutics Wins Emerging Company Showcase at MichBio Expo

ONL Therapeutics Wins Emerging Company Showcase at MichBio Expo Crain’s Detroit – 10/02/14by Tom HendersonONL Therapeutics was named the first place winner in the Emerging Company Showcase at the MichBio Expo winning a $2,500 first prize. See article in Crain’s Detroit below: Read the Article

October 2, 2014

Month: October 2014

Applications for Neuroprotection: The Next Therapeutic Category in Retina Medicine

ONL Therapeutics Wins Emerging Company Showcase at MichBio Expo